ESGCT 2021 – Sio strengthens its case in GM1 gangliosidosis
A high dose of AXO-AAV-GM1 impresses, but small patient numbers provide a reason for caution.
Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Roivant rewrites the Spac script, again
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
The Spac story departs from the script
Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
A busy year ahead for Parkinson’s disease
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
A three way battle beckons in GM1 gangliosidosis
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
